{"schema_version":"secwatch.filing_event.v1","accession":"0000019584-26-000010","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2026-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.320627+00:00","generated_at":"2026-05-15T04:38:54.156725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Chemed Q1 adjusted EPS $5.65; boosts 2026 guidance to $24.00-$24.75 on VITAS momentum","bullets":["GAAP diluted EPS $4.84, down 0.4% YoY; adjusted EPS $5.65, up 0.4% YoY.","Revenue $657.5M (+1.6%); VITAS revenue $420.0M (+3.1%); Roto-Rooter revenue $237.5M (-0.9%).","VITAS ADC up 2.2% to 22,723; admissions up 6.9%; adjusted EBITDA ex-Medicare Cap $70.8M (+0.6%), margin 16.8%.","Roto-Rooter adjusted EBITDA $53.5M (-9.6%), margin 22.5% (-218bps); acquired two franchises for $20.6M.","FY 2026 adjusted EPS guidance raised to $24.00-$24.75 from $23.25-$24.25; repurchased 500k shares for $197.7M in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000019584-26-000010","json":"https://secwatch.observer/filing/0000019584-26-000010.json","markdown":"https://secwatch.observer/filing/0000019584-26-000010.md","text":"https://secwatch.observer/filing/0000019584-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000001958426000010/0000019584-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000001958426000010/che-20260423x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:38:54.156725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"443b7360c5f10436d59930ee37b220dff441c4fe","claim":"CHEMED CORP reported first quarter ended March 31, 2026 results: revenue $657.5 million, EPS GAAP Diluted Earnings-per-Share (EPS) of $4.84.","evidence_excerpt":"quarter ended March 31, 2026, versus the comparable prior-year period.  Results for Quarter Ended March 31, 2026  Consolidated operating results: · Revenue increased 1.6% to $657.5 million · GAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4% · Adjusted Diluted EPS of $5.65, an increase of 0.4%  VITAS segment operating results: · Net Patient Revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/19584/000001958426000010/0000019584-26-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$657.5 million"},{"label":"EPS","value":"GAAP Diluted Earnings-per-Share (EPS) of $4.84"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}